3b:I[281230,["/_next/static/immutable/chunks/0l5c-zsrs2aic.js","/_next/static/immutable/chunks/3_n0rk2989-8h.js","/_next/static/immutable/chunks/3ofw495lt1gr1.js","/_next/static/immutable/chunks/3tofdpg99uc12.js","/_next/static/immutable/chunks/2rzojj6zgb9d9.js","/_next/static/immutable/chunks/42jxjvozn2thc.js","/_next/static/immutable/chunks/1jp6nkbajpbfs.js","/_next/static/immutable/chunks/3jn_lf7v27x-6.js","/_next/static/immutable/chunks/33qq2-hg37d0b.js","/_next/static/immutable/chunks/15isb0svrppbz.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/0asz50g5_lfq9.js","/_next/static/immutable/chunks/30ia-cxa0yoyc.js","/_next/static/immutable/chunks/3ghibkczd0agr.js","/_next/static/immutable/chunks/20mjl75wrar8n.js","/_next/static/immutable/chunks/3nxreg9fiyt2y.js","/_next/static/immutable/chunks/0c04lgvo3p78i.js","/_next/static/immutable/chunks/1u78gf_avpn77.js"],"PaperListPageClient"] 3e:I[70339,["/_next/static/immutable/chunks/355lxm8rh3fxr.js"],"IconMark"] 3c:T5df,Radiation-induced oral mucositis (RIOM) is a severe complication of radiotherapy (RT) for head and neck cancers, impairing quality of life and treatment adherence. Low-level laser therapy (LLLT) shows promise for reducing RIOM severity, but operator-dependent devices limit practicality. This feasibility study assessed the safety and efficacy of a novel intraoral stent-based LLLT device designed for consistent laser delivery. This prospective, single-arm, multicenter study enrolled 15 patients receiving curative RT for head and neck cancers. The stent-based device delivered laser light to 43 oral cavity points at three wavelengths (670, 830, and 910 nm) during 20-min sessions, five times weekly. The primary end point was the incidence of Grade 3 or higher RIOM (WHO oral mucositis scale). Pain severity was a secondary end point (Numeric Pain Rating Scale [NPRS]). Grade 3 or higher RIOM occurred in 6.6% of patients, significantly lower than historical rates (30%-40%). No patients reported severe pain (NPRS ≥ 8). The device was well-tolerated with no adverse effects, and all patients completed RT as planned. The intraoral stent-based LLLT device is a safe and potentially effective intervention for reducing severe RIOM. Randomized trials are warranted to confirm these findings. This study was a prospective, single-arm feasibility trial and was not registered in a clinical trial registry, as it did not meet the criteria for mandatory registration at the time of its initiation.3d:T790,ABSTRACTObjectivesRadiation‐induced oral mucositis (RIOM) is a severe complication of radiotherapy (RT) for head and neck cancers, impairing quality of life and treatment adherence. Low‐level laser therapy (LLLT) shows promise for reducing RIOM severity, but operator‐dependent devices limit practicality. This feasibility study assessed the safety and efficacy of a novel intraoral stent‐based LLLT device designed for consistent laser delivery.Materials and MethodsThis prospective, single‐arm, multicenter study enrolled 15 patients receiving curative RT for head and neck cancers. The stent‐based device delivered laser light to 43 oral cavity points at three wavelengths (670, 830, and 910 nm) during 20‐min sessions, five times weekly. The primary end point was the incidence of Grade 3 or higher RIOM (WHO oral mucositis scale). Pain severity was a secondary end point (Numeric Pain Rating Scale [NPRS]).ResultsGrade 3 or higher RIOM occurred in 6.6% of patients, significantly lower than historical rates (30%–40%). No patients reported severe pain (NPRS ≥ 8). The device was well‐tolerated with no adverse effects, and all patients completed RT as planned.ConclusionsThe intraoral stent‐based LLLT device is a safe and potentially effective intervention for reducing severe RIOM. Randomized trials are warranted to confirm these findings.Trial RegistrationThis study was a prospective, single‐arm feasibility trial and was not registered in a clinical trial registry, as it did not meet the criteria for mandatory registration at the time of its initiation.28:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Photobiomodulation: Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Photobiomodulation (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Photobiomodulation\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Photobiomodulation\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Photobiomodulation\"}]}}"}}]],["$","$L3b",null,{"title":"Photobiomodulation: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Photobiomodulation — concise summaries and practical next steps.","papers":[{"doi":"10.1016/j.ajo.2026.07.035","pmid":"42501959","title":"Cost-Effectiveness of Photobiomodulation for Intermediate Dry Age-Related Macular Degeneration: A Model-Based Analysis Using the LIGHTSITE III 24-Month Trial","journal_title":"American Journal of Ophthalmology","journal_issn":"0002-9394","published_at":"2026-07-25T00:00:00.000Z","url":"https://doi.org/10.1016/j.ajo.2026.07.035","source_score":3,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-29T13:31:07.371Z","updated_at":"2026-07-29T13:31:07.371Z","tags":[{"paper_doi":"10.1016/j.ajo.2026.07.035","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.035","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.035","tag_type":"condition","value":"Age-Related Macular Degeneration","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.035","tag_type":"condition","value":"Geographic Atrophy","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.035","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.035","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.035","tag_type":"modality","value":"Photobiomodulation","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.035","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.035","tag_type":"study_design","value":"Model-Based Cost-Effectiveness Analysis","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.035","tag_type":"warning","value":"No sample size tag is applied, as this is a modeled cohort analysis rather than an empirical study with a discrete enrolled N.","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.035","tag_type":"warning","value":"The level of evidence is rated 4 (model-based analysis); the underlying GA reduction (71.7%) comes from a single RCT (LIGHTSITE III) with no independent replication to date, which is a critical driver of the ICER.","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.035","tag_type":"warning","value":"The 'practice_changing' impact flag is applied cautiously — the authors themselves note findings are conditional on independent replication and prospective utility data.","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.035","tag_type":"warning","value":"The study was published July 25, 2026; today is July 29, 2026 — this is very recent and no post-publication peer commentary is yet available.","value_numeric":null}],"summaries":{"what_studied":"This model-based cost-effectiveness analysis evaluated photobiomodulation (PBM) vs. standard care for bilateral intermediate dry AMD in adults (BCVA 20/32–20/100) over a 10-year horizon, using a 5-state Markov model informed by 24-month LIGHTSITE III trial data and AREDS natural history rates.","key_result":"PBM produced 5.244 discounted QALYs at an incremental cost of $29,556 over 10 years (ICER: $73,910/QALY), falling below both the $100,000 and $150,000 US willingness-to-pay thresholds. The ICER remained cost-effective across most scenarios ($36,700–$117,694/QALY), except the $5,000/course pricing scenario. The 5-year national budget impact was $25.0 billion at 20% uptake.","limitations":"- The 71.7% relative GA reduction driving the model is from a single trial (LIGHTSITE III) and has not been independently replicated.\n- Quality-of-life inputs relied on indirect VFQ-25-to-EQ-5D conversion rather than prospectively collected EQ-5D data.\n- The 10-year model extrapolates well beyond the 24-month trial follow-up, introducing structural uncertainty.","practice_takeaway":"At current US pricing assumptions, PBM appears cost-effective for intermediate dry AMD and may warrant coverage consideration — but clinicians and payers should wait for independent replication of the GA reduction benefit before broad adoption. The large projected budget impact ($25B over 5 years at 20% uptake) underscores the need for robust confirmatory evidence."}},{"doi":"10.3389/fped.2026.1819736","pmid":null,"title":"Alterations in urinary metals following pulsed 660 nm photobiomodulation in a pediatric patient with autism spectrum disorder: a case report","journal_title":"Frontiers in Pediatrics","journal_issn":"2296-2360","published_at":"2026-06-23T00:00:00.000Z","url":"https://doi.org/10.3389/fped.2026.1819736","source_score":4,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-06-29T13:22:50.678Z","updated_at":"2026-06-29T13:22:50.678Z","tags":[{"paper_doi":"10.3389/fped.2026.1819736","tag_type":"age_group","value":"child","value_numeric":null},{"paper_doi":"10.3389/fped.2026.1819736","tag_type":"category","value":"Pediatrics","value_numeric":null},{"paper_doi":"10.3389/fped.2026.1819736","tag_type":"condition","value":"Autism Spectrum Disorder","value_numeric":null},{"paper_doi":"10.3389/fped.2026.1819736","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.3389/fped.2026.1819736","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.3389/fped.2026.1819736","tag_type":"modality","value":"Photobiomodulation","value_numeric":null},{"paper_doi":"10.3389/fped.2026.1819736","tag_type":"sample_size","value":"n=1","value_numeric":1},{"paper_doi":"10.3389/fped.2026.1819736","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.3389/fped.2026.1819736","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.3389/fped.2026.1819736","tag_type":"warning","value":"Generative AI (Claude, Anthropic) was used by the authors to assist in manuscript formatting and editorial refinement, per the authors' own disclosure.","value_numeric":null},{"paper_doi":"10.3389/fped.2026.1819736","tag_type":"warning","value":"Severe conflict of interest: both authors co-founded the company (Researched Elements Tech LLC) that manufactures the PBM device studied; findings should be interpreted with heightened caution.","value_numeric":null},{"paper_doi":"10.3389/fped.2026.1819736","tag_type":"warning","value":"The marked mercury rise at follow-up (8.4 µg/g with urine pH >8.0) is unexplained; alkaline urine can artifactually alter ICP-MS/MS metal recovery, and intervening exposures were not systematically documented.","value_numeric":null},{"paper_doi":"10.3389/fped.2026.1819736","tag_type":"warning","value":"Urinary aluminum increase is a temporal observation in a single patient — it cannot establish mobilization, reduced tissue burden, or any clinical benefit.","value_numeric":null}],"summaries":{"what_studied":"A single 5-year-old boy with ASD received pulsed 660 nm photobiomodulation (PBM; 3 sessions/day × 6 days) and had serial urine aluminum measured across 8 specimens (Nov 7–19, 2025) plus a 2-month follow-up (Jan 21, 2026), with 2 pre-intervention baseline specimens for comparison.","key_result":"Baseline urinary aluminum was stable at ~10 µg/g creatinine (reference <40). After PBM, aluminum rose to 58 µg/g on Day 3 and peaked at 98 µg/g on Day 7 (~tenfold increase). At 2-month follow-up, it remained elevated at 49 µg/g. Mercury exceeded reference in all specimens including baseline (Days 1–2: 2.7 and 1.8 µg/g; reference <0.7) and surged to 8.4 µg/g at follow-up.","limitations":"- **Single case, no control**: No sham-PBM arm or randomization; temporal association only, causality cannot be inferred.\n- **Urinary aluminum ≠ body burden**: Elevated urinary excretion does not confirm systemic mobilization, tissue clearance, or clinical benefit; confounders (hydration, diet, renal handling, pH) were not fully controlled.\n- **Dosimetry and conflict of interest**: Device output power, irradiance, and fluence were not independently verified; both authors co-founded the company that manufactures the PBM device.","practice_takeaway":"Do not interpret this single case as evidence that 660 nm PBM reduces aluminum burden or improves ASD outcomes — the authors themselves are explicit that it is hypothesis-generating only. Clinicians should await sham-controlled trials with validated behavioral outcomes and independent dosimetry before considering this approach."}},{"doi":"10.2147/ccid.s596645","pmid":null,"title":"Microneedling Combined with Photothermal-Biomodulated Autologous PRP to Enhance Exosome Release in Refractory Melasma: A Case Report","journal_title":"Clinical, Cosmetic and Investigational Dermatology","journal_issn":"1178-7015","published_at":"2026-05-01T00:00:00.000Z","url":"https://doi.org/10.2147/ccid.s596645","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-05-23T13:25:04.153Z","updated_at":"2026-05-23T13:25:04.153Z","tags":[{"paper_doi":"10.2147/ccid.s596645","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2147/ccid.s596645","tag_type":"brand","value":"Meta Cell Technology (MCT System)","value_numeric":null},{"paper_doi":"10.2147/ccid.s596645","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2147/ccid.s596645","tag_type":"condition","value":"Melasma","value_numeric":null},{"paper_doi":"10.2147/ccid.s596645","tag_type":"generic","value":"platelet-rich plasma","value_numeric":null},{"paper_doi":"10.2147/ccid.s596645","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.2147/ccid.s596645","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.2147/ccid.s596645","tag_type":"modality","value":"Microneedling","value_numeric":null},{"paper_doi":"10.2147/ccid.s596645","tag_type":"modality","value":"Photobiomodulation","value_numeric":null},{"paper_doi":"10.2147/ccid.s596645","tag_type":"modality","value":"Platelet-Rich Plasma","value_numeric":null},{"paper_doi":"10.2147/ccid.s596645","tag_type":"sample_size","value":"n=1","value_numeric":1},{"paper_doi":"10.2147/ccid.s596645","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.2147/ccid.s596645","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.2147/ccid.s596645","tag_type":"warning","value":"Article Processing Charges were paid by Meta Cell Technology, the manufacturer of the device used — a potential conflict of interest not declared by authors but disclosed in the funding section.","value_numeric":null},{"paper_doi":"10.2147/ccid.s596645","tag_type":"warning","value":"Study population is a single white male (Fitzpatrick II), limiting applicability to higher phototypes most commonly affected by melasma.","value_numeric":null},{"paper_doi":"10.2147/ccid.s596645","tag_type":"warning","value":"The 'Exosomes' preset used was described as exploratory with no established protocol for melasma; exosome quantification was not performed, so the claimed mechanism of action (enhanced exosome release) was not directly verified.","value_numeric":null}],"summaries":{"what_studied":"A 35-year-old male (Fitzpatrick type II) with refractory facial melasma unresponsive to prior topical and laser therapies was treated with 3 monthly sessions of robotic microneedling followed by intradermal injections of photothermal-biomodulated autologous PRP (PTBM-PRP), preconditioned with blue light (467 nm, 1 J/cm², 37°C for 10 minutes) using the Meta Cell Technology system.","key_result":"After 3 monthly sessions, marked clinical improvement was observed — visible lightening of the malar and temporal regions on photography and stereophotogrammetric comparison — with no adverse effects reported.","limitations":"- Single-case design with no control group severely limits generalizability.\n- No validated quantitative outcome score (e.g., MASI) was used; assessment was qualitative only.\n- No long-term follow-up to assess durability or recurrence risk.","practice_takeaway":"PTBM-PRP combined with microneedling showed tolerability and visual improvement in one refractory melasma case, but clinicians should not adopt this as standard care until controlled trials with standardized outcome measures confirm these findings."}},{"doi":"10.1097/iae.0000000000004822","pmid":"41791029","title":"LONG-TERM EFFICACY AND SAFETY OF PHOTOBIOMODULATION IN DRY AGE-RELATED MACULAR DEGENERATION (LIGHTSITE III: 24-MONTH ANALYSIS)","journal_title":"Retina","journal_issn":"0275-004X","published_at":"2026-03-06T00:00:00.000Z","url":"https://doi.org/10.1097/iae.0000000000004822","source_score":12,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-07T22:50:46.299Z","updated_at":"2026-05-07T22:50:46.299Z","tags":[{"paper_doi":"10.1097/iae.0000000000004822","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004822","tag_type":"brand","value":"Valeda","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004822","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004822","tag_type":"condition","value":"Dry Age-Related Macular Degeneration","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004822","tag_type":"condition","value":"Geographic Atrophy","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004822","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004822","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004822","tag_type":"modality","value":"Photobiomodulation","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004822","tag_type":"sample_size","value":"n=148 eyes (100 subjects)","value_numeric":148},{"paper_doi":"10.1097/iae.0000000000004822","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004822","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004822","tag_type":"warning","value":"Geographic atrophy incidence analysis was described as a descriptive statistic and was not multiplicity-controlled, so the P=0.007 result should be interpreted with caution.","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004822","tag_type":"warning","value":"Several co-authors are employees or paid consultants of LumiThera, the device manufacturer, which funded the trial alongside the National Eye Institute.","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004822","tag_type":"warning","value":"The nAMD conversion rate was numerically higher in the PBM group (7.5% vs. 3.6% sham), though the authors attribute this partly to a 3-fold higher baseline prevalence of high-risk (fellow-eye nAMD) subjects in the PBM arm.","value_numeric":null},{"paper_doi":"10.1097/iae.0000000000004822","tag_type":"warning","value":"The sham arm used reduced-dose PBM (not a true placebo), which may have attenuated the observed between-group difference — the true effect size vs. no treatment could be larger.","value_numeric":null}],"summaries":{"what_studied":"LIGHTSITE III evaluated multiwavelength photobiomodulation (PBM) using the Valeda Light Delivery System (590, 660, 850 nm) versus sham in 148 eyes (100 subjects) with dry (nonexudative) AMD over 24 months, with 9-session treatment series every 4 months.","key_result":"PBM met the prespecified primary endpoint at Month 21: +6.2 letter BCVA gain vs. sham (P=0.0036), sustained at Month 24 (+5.6 letters, P=0.0024). Incident geographic atrophy at Month 24 was 6.8% (PBM) vs. 24.0% (sham) (P=0.007). Vision-related QoL (VFQ-25) improved significantly in the PBM group at Month 21 (P=0.02), while the sham group declined. No phototoxicity was observed.","limitations":"- The sham was a reduced-dose active control (not inert), likely producing a small biological effect and compressing the between-group difference.\n- Small sample size (n=100 subjects) limits subgroup power; GA lesion area analyses were underpowered.\n- Industry sponsorship (LumiThera) with several authors as company employees or consultants.","practice_takeaway":"For patients with intermediate dry AMD, multiwavelength PBM delivered every 4 months improved visual acuity by ~6 letters and cut new geographic atrophy incidence by roughly two-thirds compared to sham over 2 years. The favorable safety profile and high compliance (83% fully adherent in PBM group) support its use as an adjunctive, non-pharmacologic intervention in this population."}},{"doi":"10.1002/lsm.70069","pmid":"41058057","title":"Feasibility Study of a Novel Stent‐Based Low‐Level Laser Therapy Device for Reducing Severe Radiation‐Induced Oral Mucositis","journal_title":"Lasers in Surgery and Medicine","journal_issn":"0196-8092","published_at":"2025-10-08T00:00:00.000Z","url":"https://doi.org/10.1002/lsm.70069","source_score":2,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-09","doi":"10.1002/lsm.70069","days":"7","issn":"0196-8092","rank":"10","field":"Clinical Medicine","score":"2","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1002/lsm.70069","title":"Feasibility Study of a Novel Stent-Based Low-Level Laser Therapy Device for Reducing Severe Radiation-Induced Oral Mucositis.","journal":"Lasers in surgery and medicine","methods":"","results":"Grade 3 or higher RIOM occurred in 6.6% of patients, significantly lower than historical rates (30%-40%). No patients reported severe pain (NPRS ≥ 8). The device was well-tolerated with no adverse effects, and all patients completed RT as planned.","abstract":"$3c","keywords":["feasibility studies","head and neck neoplasms","low‐level light therapy","oral mucositis","radiotherapy"],"pubmed_id":"41058057","conclusions":"","publication_date":"2025-10-08T00:00:00"},"crossref":{"DOI":"10.1002/lsm.70069","URL":"https://doi.org/10.1002/lsm.70069","ISSN":["0196-8092","1096-9101"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/lsm.70069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Feasibility Study of a Novel Stent‐Based Low‐Level Laser Therapy Device for Reducing Severe Radiation‐Induced Oral Mucositis"],"author":[{"given":"Jong Yun","family":"Baek","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea"}]},{"given":"Kyungmi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea"}]},{"given":"Tae Hoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea"}]},{"given":"Sung Uk","family":"Lee","sequence":"additional","affiliation":[{"name":"Proton Therapy Center, Research Institute and Hospital National Cancer Center Goyang‐si South Korea"}]},{"given":"Sung Ho","family":"Moon","sequence":"additional","affiliation":[{"name":"Proton Therapy Center, Research Institute and Hospital National Cancer Center Goyang‐si South Korea"}]},{"given":"In Young","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Soonchunhyang University Hospital Cheonan South Korea"}]},{"given":"Keun‐Yong","family":"Eom","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Seoul National University Bundang Hospital, Seoul National University College of Medicine Seongnam South Korea"}]},{"given":"Dongryul","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea"}]}],"issued":{"date-parts":[[2025,10,7]]},"member":"311","prefix":"10.1002","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2025-10-08T04:21:53Z","timestamp":1759897313000,"date-parts":[[2025,10,8]]},"indexed":{"date-time":"2025-10-08T04:42:18Z","timestamp":1759898538373,"date-parts":[[2025,10,8]]},"license":[{"URL":"http://creativecommons.org/licenses/by-nc/4.0/","start":{"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000,"date-parts":[[2025,10,7]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$3d","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1002/lsm.70069"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-04-16"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-24"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-10-07"}],"deposited":{"date-time":"2025-10-08T04:21:56Z","timestamp":1759897316000,"date-parts":[[2025,10,8]]},"issn-type":[{"type":"print","value":"0196-8092"},{"type":"electronic","value":"1096-9101"}],"published":{"date-parts":[[2025,10,7]]},"publisher":"Wiley","reference":[{"DOI":"10.4143/crt.2023.447","key":"e_1_2_10_2_1","year":"2023","issue":null,"author":"Kang M. J.","volume":"55","first-page":"385","unstructured":null,"article-title":"Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2020","journal-title":"Cancer Research and Treatment","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41415-022-5151-4","key":"e_1_2_10_3_1","year":"2022","issue":null,"author":"Creaney G.","volume":"233","first-page":"787","unstructured":null,"article-title":"Head and Neck Cancer in the UK: What Was the Stage Before COVID‐19? UK Cancer Registries Analysis (2011–2018)","journal-title":"British Dental Journal","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(21)01550-6","key":"e_1_2_10_4_1","year":"2021","issue":null,"author":"Mody M. D.","volume":"398","first-page":"2289","unstructured":null,"article-title":"Head and Neck Cancer","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0167-8140(02)00404-8","key":"e_1_2_10_5_1","year":"2003","issue":null,"author":"Trotti A.","volume":"66","first-page":"253","unstructured":null,"article-title":"Mucositis Incidence, Severity and Associated Outcomes in Patients With Head and Neck Cancer Receiving Radiotherapy With or Without Chemotherapy: A Systematic Literature Review","journal-title":"Radiotherapy and Oncology","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamanetworkopen.2023.37265","key":"e_1_2_10_6_1","year":"2023","issue":null,"author":"Iovoli A. J.","volume":"6","first-page":null,"unstructured":null,"article-title":"Severe Oral Mucositis After Intensity‐Modulated Radiation Therapy for Head and Neck Cancer","journal-title":"JAMA Network Open","doi-asserted-by":"crossref"},{"DOI":"10.1002/cncr.21622","key":"e_1_2_10_7_1","year":"2006","issue":null,"author":"Vera‐Llonch M.","volume":"106","first-page":"329","unstructured":null,"article-title":"Oral Mucositis in Patients Undergoing Radiation Treatment for Head and Neck Carcinoma","journal-title":"Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00520-009-0771-7","key":"e_1_2_10_8_1","year":"2010","issue":null,"author":"Cheng K. K. F.","volume":"18","first-page":"1477","unstructured":null,"article-title":"Severe Oral Mucositis Associated With Cancer Therapy: Impact on Oral Functional Status and Quality of Life","journal-title":"Supportive Care in Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00520-016-3152-z","key":"e_1_2_10_9_1","year":"2016","issue":null,"author":"Zecha J. A. E. M.","volume":"24","first-page":"2781","unstructured":null,"article-title":"Low Level Laser Therapy/Photobiomodulation in the Management of Side Effects of Chemoradiation Therapy in Head and Neck Cancer: Part 1: Mechanisms of Action, Dosimetric, and Safety Considerations","journal-title":"Supportive Care in Cancer","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_10_10_1","year":"2010","issue":null,"author":"Clarkson J. E.","volume":null,"first-page":null,"unstructured":null,"article-title":"Interventions for Treating Oral Mucositis for Patients With Cancer Receiving Treatment","journal-title":"Cochrane Database of Systematic Reviews","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_11_1","year":"2011","issue":null,"author":"Worthington H. V.","volume":null,"first-page":null,"unstructured":null,"article-title":"Interventions for Preventing Oral Mucositis for Patients With Cancer Receiving Treatment","journal-title":"Cochrane Database of Systematic Reviews","doi-asserted-by":null},{"DOI":"10.1007/s00520-011-1202-0","key":"e_1_2_10_12_1","year":"2011","issue":null,"author":"Bjordal J. M.","volume":"19","first-page":"1069","unstructured":null,"article-title":"A Systematic Review With Meta‐Analysis of the Effect of Low‐Level Laser Therapy (LLLT) in Cancer Therapy‐Induced Oral Mucositis","journal-title":"Supportive Care in Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1097/CCO.0b013e328352eaa3","key":"e_1_2_10_13_1","year":"2012","issue":null,"author":"Bensadoun R. J.","volume":"24","first-page":"363","unstructured":null,"article-title":"Low‐Level Laser Therapy in the Prevention and Treatment of Cancer Therapy‐Induced Mucositis: 2012 State of the Art Based on Literature Review and Meta‐Analysis","journal-title":"Current Opinion in Oncology","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00520-012-1605-6","key":"e_1_2_10_14_1","year":"2013","issue":null,"author":"Migliorati C.","volume":"21","first-page":"333","unstructured":null,"article-title":"Systematic Review of Laser and Other Light Therapy for the Management of Oral Mucositis in Cancer Patients","journal-title":"Supportive Care in Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pone.0107418","key":"e_1_2_10_15_1","year":"2014","issue":null,"author":"Oberoi S.","volume":"9","first-page":null,"unstructured":null,"article-title":"Effect of Prophylactic Low Level Laser Therapy on Oral Mucositis: A Systematic Review and Meta‐Analysis","journal-title":"PLoS One","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00520-019-04890-2","key":"e_1_2_10_16_1","year":"2019","issue":null,"author":"Zadik Y.","volume":"27","first-page":"3969","unstructured":null,"article-title":"Systematic Review of Photobiomodulation for the Management of Oral Mucositis in Cancer Patients and Clinical Practice Guidelines","journal-title":"Supportive Care in Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1007/s10103-023-03940-w","key":"e_1_2_10_17_1","year":"2023","issue":"1","author":"Potrich A. R.","volume":"39","first-page":"1","unstructured":null,"article-title":"Impact of Photobiomodulation for Prevention of Oral Mucositis on the Quality of Life of Patients With Head and Neck Cancer: A Systematic Review","journal-title":"Lasers in Medical Science","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00520-023-08105-7","key":"e_1_2_10_18_1","year":"2023","issue":null,"author":"Cruz A. R.","volume":"31","first-page":"645","unstructured":null,"article-title":"Efficacy of Photobiomodulation in the Treatment of Oral Mucositis in Patients Undergoing Antineoplastic Therapy: Systematic Review and Meta‐Analysis","journal-title":"Supportive Care in Cancer","doi-asserted-by":"crossref"},{"DOI":"10.5005/jp-journals-10024-3277","key":"e_1_2_10_19_1","year":"2022","issue":null,"author":"Carli J. P.","volume":"23","first-page":"31","unstructured":null,"article-title":"Low‐Level Laser Therapy in the Management of Oral Mucositis Induced by Radiotherapy: A Randomized Double‐Blind Clinical Trial","journal-title":"Journal of Contemporary Dental Practice","doi-asserted-by":"crossref"},{"DOI":"10.1002/cncr.33100","key":"e_1_2_10_20_1","year":"2020","issue":null,"author":"Elad S.","volume":"126","first-page":"4423","unstructured":null,"article-title":"MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy","journal-title":"Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.radonc.2013.08.010","key":"e_1_2_10_21_1","year":"2013","issue":null,"author":"Antunes H. S.","volume":"109","first-page":"297","unstructured":null,"article-title":"Phase III Trial of Low‐Level Laser Therapy to Prevent Oral Mucositis in Head and Neck Cancer Patients Treated With Concurrent Chemoradiation","journal-title":"Radiotherapy and Oncology","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.oraloncology.2017.05.018","key":"e_1_2_10_22_1","year":"2017","issue":null,"author":"Antunes H. S.","volume":"71","first-page":"11","unstructured":null,"article-title":"Long‐Term Survival of a Randomized Phase III Trial of Head and Neck Cancer Patients Receiving Concurrent Chemoradiation Therapy With or Without Low‐Level Laser Therapy (LLLT) to Prevent Oral Mucositis","journal-title":"Oral Oncology","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00520-018-4046-z","key":"e_1_2_10_23_1","year":"2018","issue":null,"author":"Brandão T. B.","volume":"26","first-page":"2417","unstructured":null,"article-title":"Locally Advanced Oral Squamous Cell Carcinoma Patients Treated With Photobiomodulation for Prevention of Oral Mucositis: Retrospective Outcomes and Safety Analyses","journal-title":"Supportive Care in Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.oraloncology.2016.01.005","key":"e_1_2_10_24_1","year":"2016","issue":null,"author":"Sonis S. T.","volume":"54","first-page":"7","unstructured":null,"article-title":"Could the Biological Robustness of Low Level Laser Therapy (Photobiomodulation) Impact Its Use in the Management of Mucositis in Head and Neck Cancer Patients","journal-title":"Oral Oncology","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.oraloncology.2019.04.004","key":"e_1_2_10_25_1","year":"2019","issue":null,"author":"Pauli Paglioni M.","volume":"93","first-page":"21","unstructured":null,"article-title":"Tumor Safety and Side Effects of Photobiomodulation Therapy Used for Prevention and Management of Cancer Treatment Toxicities. A Systematic Review","journal-title":"Oral Oncology","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1002/lsm.70069"],"article-number":"lsm.70069","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Lasers in Surgery and Medicine"],"reference-count":24,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10,7]]},"references-count":24,"short-container-title":["Lasers Surg Med"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1002/lsm.70069","is_oa":true,"title":"Feasibility Study of a Novel Stent‐Based Low‐Level Laser Therapy Device for Reducing Severe Radiation‐Induced Oral Mucositis","updated":"2025-10-10T00:14:49+00:00","published_date":"2025-10-07","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lsm.70069","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lsm.70069","url_for_landing_page":"https://doi.org/10.1002/lsm.70069"}}},"created_at":"2025-10-13T07:32:37.233Z","updated_at":"2025-10-15T07:01:11.375Z","tags":[{"paper_doi":"10.1002/lsm.70069","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"condition","value":"Head And Neck Cancer","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"condition","value":"Radiation-Induced Oral Mucositis","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"modality","value":"Photobiomodulation","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"sample_size","value":"n=15","value_numeric":15},{"paper_doi":"10.1002/lsm.70069","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"study_design","value":"Prospective Single-Arm Trial","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"warning","value":"Design classification is approximate; this was a prospective, single‑arm feasibility study.","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"warning","value":"Efficacy comparisons rely on historical rates rather than a concurrent control group.","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"warning","value":"The report states lower rates versus historical controls but does not provide statistical testing details.","value_numeric":null}],"summaries":{"what_studied":"Prospective, single‑arm, multicenter feasibility study (n=15) in adults receiving curative head and neck radiotherapy, testing an intraoral stent‑based low‑level laser therapy that delivered light to 43 oral sites (670, 830, 910 nm) for 20 minutes, five times weekly from week 2 of RT through completion (study period September 2023–May 2024). The primary endpoint was incidence of WHO grade ≥3 radiation‑induced oral mucositis; pain (Numeric Pain Rating Scale) was secondary, with a final assessment 4 weeks post‑RT.","key_result":"Grade ≥3 mucositis occurred in 1/15 patients (6.6%) versus historical rates of 30%–40%. No patient reported severe pain (NPRS ≥8); four reported pain up to 4, all completed RT (five had 1–5‑day interruptions), and no device‑related adverse effects were observed.","limitations":"Single‑arm design with comparisons to historical controls, without a concurrent comparator. Small sample size (n=15) limits precision. Short follow‑up (final evaluation 4 weeks post‑RT) and no photographic documentation.","practice_takeaway":"Stent‑based photobiomodulation was feasible, well tolerated, and associated with a low rate of severe mucositis in this small cohort. Continue using LLLT per guidelines where applicable, and await randomized trials before adopting this stent device broadly."}}],"initialOffset":5,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Photobiomodulation"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Photobiomodulation"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Photobiomodulation"}}}]] 2b:null 2f:[["$","title","0",{"children":"Photobiomodulation: Research & Clinical Takeaways | ReachRx"}],["$","meta","1",{"name":"description","content":"Explore peer-reviewed papers on Photobiomodulation (modality). Clinician-written summaries and actionable practice insights. Updated daily."}],["$","meta","2",{"name":"apple-mobile-web-app-capable","content":"yes"}],["$","meta","3",{"name":"msapplication-config","content":"/browserconfig.xml"}],["$","meta","4",{"name":"msapplication-tap-highlight","content":"no"}],["$","link","5",{"rel":"canonical","href":"https://www.reachrx.ai/hub/tag/modality/Photobiomodulation"}],["$","meta","6",{"name":"format-detection","content":"telephone=no"}],["$","meta","7",{"name":"mobile-web-app-capable","content":"yes"}],["$","meta","8",{"name":"apple-mobile-web-app-status-bar-style","content":"black-translucent"}],["$","meta","9",{"property":"og:title","content":"Photobiomodulation: Research & Clinical Takeaways | ReachRx"}],["$","meta","10",{"property":"og:description","content":"Explore peer-reviewed papers on Photobiomodulation (modality). Clinician-written summaries and actionable practice insights. Updated daily."}],["$","meta","11",{"property":"og:url","content":"https://www.reachrx.ai/hub/tag/modality/Photobiomodulation"}],["$","meta","12",{"property":"og:site_name","content":"ReachRx"}],["$","meta","13",{"property":"og:locale","content":"en_US"}],["$","meta","14",{"property":"og:image","content":"https://www.reachrx.ai/reachrx_branding/reachrx-logo-metaimage.png"}],["$","meta","15",{"property":"og:image:type","content":"image/png"}],["$","meta","16",{"property":"og:image:width","content":"1200"}],["$","meta","17",{"property":"og:image:height","content":"630"}],["$","meta","18",{"property":"og:type","content":"website"}],["$","meta","19",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","20",{"name":"twitter:creator","content":"@Reach_Rx"}],["$","meta","21",{"name":"twitter:title","content":"Photobiomodulation: Research & Clinical Takeaways | ReachRx"}],["$","meta","22",{"name":"twitter:description","content":"Explore peer-reviewed papers on Photobiomodulation (modality). Clinician-written summaries and actionable practice insights. Updated daily."}],["$","meta","23",{"name":"twitter:image","content":"https://www.reachrx.ai/reachrx_branding/reachrx-logo-metaimage.png"}],["$","link","24",{"rel":"shortcut icon","href":"/favicon.ico"}],["$","link","25",{"rel":"apple-touch-icon","href":"/apple-touch-icon.png","sizes":"180x180"}],["$","link","26",{"rel":"mask-icon","href":"/safari-pinned-tab.svg","color":"#000000"}],["$","$L3e","27",{}]]

Papers

Papers